Adenoviral-mediated gene transfer of ectodysplasin-A2 results in induction of apoptosis and cell-cycle arrest in osteosarcoma cell lines

Cancer Gene Therapy

Volumn 14, Issue 11, 2007, Pages 927-933

  Chang, B ^a   Punj, V ^b   Shindo, M ^a,c   Chaudhary, P M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Ectodysplasin A2; EDA A2; Osteosarcoma; X linked ectodermal dysplasia receptor; XEDAR

Indexed keywords

ADENOVIRUS VECTOR; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CASPASE 3; CASPASE 8; CASPASE 9; ECTODYSPLASIN A; ECTODYSPLASIN A2; RECEPTOR; UNCLASSIFIED DRUG; X LINKED ECTODERMAL DYSPLASIA RECEPTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TRANSFER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; RECEPTOR GENE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; APOPTOSIS; BONE NEOPLASMS; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ECTODYSPLASINS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; OSTEOSARCOMA; XEDAR RECEPTOR;

EID: 35048876585     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701078     Document Type: Article

References (25)

1. El-Deiry WS, ed. Death Receptors in Cancer Therapy. Humana Press: Totowa, 2005.
2. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004; 23: 2950-2966.
3. Chaudhary PM. Death receptor signaling in embryonic ectodermal development. In: El-Deiry WS (ed). Death Receptors in Cancer Therapy. Humana Press: Totowa, 2005: 83-92.
4. Mikkola ML, Pispa J, Pekkanen M, Paulin L, Nieminen P, Kere J et al. Ectodysplasin, a protein required for epithelial morphogenesis, is a novel TNF homologue and promotes cell-matrix adhesion. Mech Dev 1999; 88: 133-146.
5. Bayes M, Hartung AJ, Ezer S, Pispa J, Thesleff I, Srivastava AK et al. The anhidrotic ectodermal dysplasia gene (EDA) undergoes alternative splicing and encodes ectodysplasin-A with deletion mutations in collagenous repeats. Hum Mol Genet 1998; 7: 1661-1669.
6. Srivastava AK, Pispa J, Hartung AJ, Du Y, Ezer S, Jenks T et al. The Tabby phenotype is caused by mutation in a mouse homologue of the EDA gene that reveals novel mouse and human exons and encodes a protein (ectodysplasin-A) with collagenous domains. Proc Natl Acad Sci USA 1997; 94: 13069-13074.
7. Yan M, Wang LC, Hymowitz SG, Schilbach S, Lee J, Goddard A et al. Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science 2000; 290: 523-527.
8. Sinha SK, Zachariah S, Quinones HI, Shindo M, Chaudhary PM. Role of TRAF3 and -6 in the activation of the NF-kappa B and JNK pathways by X-linked ectodermal dysplasia receptor. J Biol Chem 2002; 277: 44953-44961.
9. Sinha SK, Chaudhary PM. Induction of apoptosis by X-linked ectodermal dysplasia receptor via a caspase 8-dependent mechanism. J Biol Chem 2004; 279: 41873-41881.
10. Chang B, Chaudhary PM. High level production and onestep purification of biologically active ectodysplasin A1 and A2 immunoadhesins using the baculovirus/insect cell expression system. Protein Expr Purif 2004; 37: 162-169.
11. Sun Q, Zachariah S, Chaudhary PM. The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation. J Biol Chem 2003; 278: 52437-52445.
12. Matta H, Chaudhary PM. Activation of alternative NF-kappa B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1 beta-converting enzyme inhibitory protein (vFLIP). Proc Natl Acad Sci USA 2004; 101: 9399-9404.
13. Mogi M, Togari A. Activation of caspases is required for osteoblastic differentiation. J Biol Chem 2003; 278: 47477-47482.
14. Mikkola ML, Thesleff I. Ectodysplasin signaling in development. Cytokine Growth Factor Rev 2003; 14: 211-224.
15. Su H, Bidere N, Zheng L, Cubre A, Sakai K, Dale J et al. Requirement for caspase-8 in NF-kappaB activation by antigen receptor. Science 2005; 307: 1465-1468.
16. Kennedy NJ, Kataoka T, Tschopp J, Budd RC. Caspase activation is required for T cell proliferation. J Exp Med 1999; 190: 1891-1896.
17. Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 2002; 419: 395-399.
18. Fernando P, Kelly JF, Balazsi K, Slack RS, Megeney LA. Caspase 3 activity is required for skeletal muscle differentiation. Proc Natl Acad Sci USA 2002; 99: 11025-11030.
19. Sordet O, Rebe C, Plenchette S, Zermati Y, Hermine O, Vainchenker W et al. Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood 2002; 100: 4446-4453.
20. Miura M, Chen XD, Allen MR, Bi Y, Gronthos S, Seo BM et al. A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest 2004; 114: 1704-1713.
21. Wittig JC, Bickels J, Priebat D, Jelinek J, Kellar-Graney K, Shmookler B et al. Osteosarcoma: a multidisciplinary approach to diagnosis and treatment. Am Fam Physician 2002; 65: 1123-1132.
22. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9: 422-441.
23. Fulda S, Debatin KM. Combination of chemotherapy and death ligands in cancer therapy. In: El-Deiry WS (ed.). Death Receptors in Cancer Therapy. Humana Press: Totowa, NJ, USA, 2005: 355-366.
24. Grunhagen DJ, Brunstein F, ten Hagen TL, van Geel AN, de Wilt JH, Eggermont AM. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res 2004; 120: 65-79.
25. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003; 10: 66-75.